ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Improvement in quality of life with Risperidone augmentation in treatment-resistant depression


	Home


	Shopping Cart


	Contact Us


	IRBD.ORG


	EUBF.ORG

All Enquiries:: +44 (0)20 8487 1421

Search:

Advanced search

Printable version

Categories

Help

ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Improvement in quality of life with Risperidone augmentation in treatment-resistant depression

Vol 2 - Iss 1 - Short Communication - Improvement in quality of life with Risperidone augmentation in treatment-resistant depression #80

Improvement in quality of life with Risperidone augmentation in treatment-resistant depression David Walling,1 Marcia FT Rupnow,2 Carla Canuso,2 Ibrahim Turkoz,2 Mark Rapaport3 1 CNS Network, Garden Grove, CA, USA; 2 Janssen Pharmaceutica Products, L.P., Titusville, NJ, USA; 3 Cedars-Sinai Medical Center, Los Angeles, CA, USA Objective: To evaluate the effect of adjunctive risperidone treatment on quality of life in patients with treatment-resistant depression (TRD). Methods: Data from the open-label treatment phase (4-6 weeks) of an international study designed to evaluate the efficacy, safety, and maintenance effect of risperidone augmentation to SSRI-treatment in TRD. Quality of life was evaluated using the short form of Quality-of-Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Change in Q-LES-Q from baseline was analyzed by paired t-test. Correlation analyses between MADRS and Q-LES-Q change scores were performed using Pearson method. Results: This analysis included 386 subjects, mean age 47.1. Baseline and endpoint mean (SD) Q-LES-Q scores were 42.8 (14.6) and 56.0 (18.6), indicating an improvement of 13.2 with risperidone augmentation (P<.0001). Significant improvements were observed as early as day 7 (P<.0001). Q-LES-Q item 15, medication satisfaction, was rated as good or very good by 61% of subjects. Correlation between Q-LES-Q and MADRS total change scores at endpoint was –0.6. Conclusions: These findings suggest that augmentation with risperidone rapidly and significantly improves quality of life in TRD patients. Consistent with previous work, the correlation between Q-LES-Q and MADRS indicate a meaningful relationship between quality of life improvement and symptom relief. Supported by Janssen Pharmaceuica Products, L.P. References: Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256-259. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.

Details

Price: €0.01

Options

Quantity

Add to cart

Send to friend

Your name: *

Your e-mail: *

Recipient's e-mail: *

Send to friend

Your cart

	Cart is empty

View cart
Checkout

Authentication

Username

Password

Recover password

If Javascript is disabled in your browser click here